| Authors: |
Rönnholm J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Weiner S; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Fuchs J; Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Thorsell A; Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Sihlbom C; Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Dugom L; Target ALS Foundation, NY, New York, USA., Easton A; Target ALS Foundation, NY, New York, USA., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.; Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin, University of Wisconsin-Madison, Madison, WI, USA.; Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.; Dementia Research Institute, University College London, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Centre for Brain Research, Indian Institute of Science, Bangalore, India., Gobom J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. johan.gobom@neuro.gu.se.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. johan.gobom@neuro.gu.se. |
